Therapeutic Solutions International receives landmark patent for treatment of cancer and COVID-19
QuadraMune® The commercially available “nutraceutical checkpoint inhibitor” has been shown to target the immunosuppressive pathway of indolamine 2,3 deoxygenase.
OCEANSIDE, California, December 28, 2021– (BUSINESS WIRE) – Therapeutic Solutions International today announced that it has received a Notice of Authorization from the United States Patent and Trademark Office for its patent application entitled “Nutraceuticals for Suppressing Indolamine 2,3 Deoxygenase ”.
To the Company’s knowledge, this is the first patent granted for a nutraceutical supplement to stimulate the immune system by blocking the immunosuppressive activities used by cancer and viruses in the IDO pathway. The supplement, called “QuadraMune®” is commercially available on the Company’s website and through Amazon.
Many drugs such as Optivo®, Yervoy® and Keytruda® have been approved by the FDA for the treatment of cancers by boosting immunity while blocking the mechanisms of immune inhibition. This class of drugs, called “checkpoint inhibitors,” represents a market of $ 15.2 billion per year.1.
“The indolamine 2,3 deoxygenase (IDO) pathway is considered to be one of the major immunological checkpoints on the basis that blocking small molecules from this pathway results in the immune destruction of tumors in animals.” said Dr Thomas Ichim, Board Member and co-inventor of the patent. “Unfortunately, previous approaches to suppress this pathway relied on toxic compounds that have not performed well in clinical trials, in part due to the inability to deliver sufficient doses without suggesting toxicity. excited about the possibility that QuadraMune®, a nutraceutical composition that is commercially available, may act as a potent immune booster targeting the IDO pathway without the drawbacks of other approaches. “
In 20132 then in 20183Dr. Ichim and colleagues have published regression of breast cancer by inhibiting the IDO pathway using an RNA interference approach. The current data and the granted patent represent years of fundamental scientific study into the relationship between IDO and the immune system.
“As a physician who sees firsthand the ravages of cancer and viruses, I am extremely excited about our ability to modulate critical immunological pathways using natural ingredients such as pterostilbene, thymoquinone, gallate d ‘epigallocatechin and sulforaphane,’ said Dr James Veltmeyer, Chief Physician of the Company and Co-inventor of the patent. “What is particularly important is that after our patents were filed, many independent universities validated the anti-COVID activity of the individual ingredients. These studies are summarized in our previous press release.4. “
“The acceptance of our data by the United States Patent Office upon granting the current patent is a major achievement for the company,” said Timothy Dixon, President and CEO and co-inventor of the patent. “The Company has filed numerous patent applications covering multiple nutraceuticals and uses, including; # 16/898472 titled “Nutraceuticals for reducing myeloid suppressing cells” and c) # 16/907335 titled “Treatment of SARS-CoV-2 with dendritic cells for innate and / or adaptive immunity”.
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International focuses on immune modulation for the treatment of several specific diseases. The company’s website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/
1 Global Checkpoint Inhibitors Market (2021 to 2030)
2 Silencing IDO in dendritic cells: A new approach to improve cancer immunotherapy in a mouse model of breast cancer – Zheng – 2013
3 A new cancer immunotherapy via the simultaneous mobilization of DCs and the silencing of the IDO gene targeted on DCs using an immunostimulating nanosystem – Zhang – 2018
4 Therapeutic Solutions International discusses claims of possible COVID-19 suppressive activity of QuadraMune ™ ingredients by independent universities after patent filing
See the source version on businesswire.com: https://www.businesswire.com/news/home/20211228005154/en/
Timothy G. Dixon